Treatment of Menstrual Cycle Alterations in Women with PCOS of Phenotype D Using Dietary Supplementation That Combines Diosgenin, Vitamin D and Alpha-lactalbumin

In this study, female patients diagnosed with PCOS of phenotype D will be enrolled. They generally display the following characteristics: menstrual cycle alterations; polycystic ovary morphology at ultrasound; normal blood levels of androgen, particularly testosterone; no signs of clinical hyperandrogenism.
Current treatments for this condition include insulin sensitizers (such as metformin) and hormonal contraceptives. However, this specific phenotype of PCOS do not feature metabolic or hormonal alterations, and the efficacy of these treatments has lately been questioned.
In the present clinical trial, patients will be given a dietary supplement containing Dioscorea extract (source of Diosgenin, a natural analog of progesterone), vitamin D and alpha-lactalbumin for six month. Restoration of regular menstrual cycle and physiological ultrasound appearance of the ovaries will be the primary goal of the intervention.

Start Date14 Oct 2024

Sponsor / Collaborator

Lo.Li.Pharma s.r.l.

JPRN-UMIN000054724

/ SuspendedNot ApplicableIIT

Study to confirm the safety of continuous intake of diosgenin - Study to confirm the safety of continuous intake of diosgenin

Start Date25 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Diosgenin

100 Translational Medicine associated with Diosgenin

100 Patents (Medical) associated with Diosgenin

4,040

Literatures (Medical) associated with Diosgenin

01 Aug 2025·Journal of Biotechnology

Enhancing secondary metabolite biosynthesis from ethnomedicinal plant Solanum nigrum L. through cytogenetically stable mass propagation, transgenic hairy root induction, and using different LED light and culture vessels for hairy root culture

Article

Author: Ghosh, Biswajit ; Biswas, Diptesh ; Halder, Tarun

This study aimed for stepwise enhancement of bioactive compound production in ethnomedicinal plant Solanum nigrum through novel approaches of micropropagation, hairy root induction, and treatment of hairy roots with various physical conditions. Polyamines were first-time used for in vitro shoot multiplication of S. nigrum, where highest shoot numbers (55.70 ± 0.64) were observed in Murashige and Skoog's (MS) medium with 0.2 mg/L thiadiazuron + 20 mg/L spermine, whereas maximum root numbers (34.20 ± 0.80) were observed in ½MS medium with 0.5 mg/L indole-3-acetic acid. Pioneer studies of cytogenetical fidelity assessment through inter simple sequence repeat (ISSR) and start codon targeted (SCoT) markers, and chromosome analysis approved genetic uniformity in regenerated plants. Cent percent hairy roots were induced from in vitro S. nigrum leaves (25-30 roots/explant) using Agrobacterium rhizogenes (A4 strain). PCR of transgenes confirmed the transformed nature and absence of bacterial contamination in hairy roots. HPLC studies indicated greater secondary metabolites in hairy roots than in vivo and in vitro plants. Hairy root culture with different culture vessels revealed overall better biomass gain in tightly sealed vessels. However, hairy root cultures treated with red light showed highest biomass accumulation in fresh (2380.13 ± 16.83 mg) and dry (174.66 ± 4.68 mg) weight with maximum solasodine (3.25 ± 0.04 mg/g) and diosgenin (1.03 ± 0.02 mg/g) contents, whereas optimal production of caffeic (3.51 ± 0.05 mg/g), coumaric (2.53 ± 0.06 mg/g), ellagic (0.18 ± 0.02 mg/g), and ferulic (2.17 ± 0.03 mg/g) acid production was found in blue light. These reproducible protocols can be utilized in future bioreactor-mediated mass-culture of hairy roots for commercial-level secondary metabolite production from S. nigrum.

01 Jun 2025·European Journal of Pharmacology

Efficacy of mangiferin, kaempferol, and diosgenin on models of depression: A systematic review and network meta-analysis of rodent studies

Article

Author: Chen, Cong-Ya ; Lei, Lan ; Yang, Xuan ; Wang, Yu-Fei ; Guo, Zhen-Yu ; Zhang, Yi

BACKGROUNDMangiferin (MGF), kaempferol (KMP), and diosgenin (DIO) are active compounds extracted from the dried rhizomes of Anemarrhena asphodeloides Bunge. that are proven to have antidepressant activity. However, no studies comprehensively compare and analyze the efficacy of MGF, KMP, and DIO.METHODSWe searched electronic databases (e.g., Cochrane Library, Embase, Scopus, and PubMed) for studies of three compounds in rodents from inception to October 2024, performing a systematic review and network meta-analysis. We used animal behavioral tests as outcome indicators, including the forced swimming test, tail suspension test, and sucrose preference test.RESULTSA total of ten studies were included, involving 440 animals and six interventions. In the forced swimming test, the efficacy of fluoxetine was superior to KMP, MGF, and DIO. In the tail suspension test, DIO was more effective than fluoxetine, MGF, and KMP. In the sucrose preference test, the efficacy of fluoxetine was superior to MGF, DIO, and KMP. Specifically, MGF, KMP, and DIO significantly reduced the immobility time of the FST or TST and increased the sucrose preference index.CONCLUSIONSMGF, KMP, and DIO significantly improved depression-like behaviors of rodents, providing evidence for further development of new clinical antidepressants. Also, MGF, KMP, and DIO exert antidepressant effects primarily through anti-inflammatory, anti-oxidative stress, and regulation of neurotrophic factor and neurotransmitter levels.

01 Jun 2025·The Journal of Nutritional Biochemistry

Diosgenin alleviates lipid accumulation in NAFLD through the pathways of ferroptosis defensive and executive system

Article

Author: Meng, Decheng ; Jiang, Wenying ; Chen, Suwen ; Yu, Hongzhuan ; Wang, Dongxian ; Wang, Linya ; Yu, Wenfei ; Yin, Guoliang ; Zhang, Xin ; Zhang, Fengxia ; Liu, Hongshuai

The most prevalent liver condition globally is non-alcoholic fatty liver disease (NAFLD), for which no approved therapies currently exist. Diosgenin, an important component in plants from the Leguminosae, Dioscoreaceae, and Solanaceae families, has demonstrated considerable anti-inflammatory and antioxidant effects. Nonetheless, the specific mechanism by which it may act in managing NAFLD remains unclear. Our research aims to explore the effects and molecular mechanisms of DG on NAFLD by utilizing both in vivo and in vitro experimental approaches. To investigate the effect of DG on hepatic steatosis, we used Sprague-Dawley rats induced by a high-fat diet (HFD) and HepG2 cells exposed to free fatty acids. Oil red O staining and hematoxylin-eosin (H&E) staining were used to explore lipid accumulation and hepatic degeneration. ROS staining, SOD, MDA, and Fe²⁺kits were used to detect the indexes related to oxidative stress in ferroptosis in hepatic tissues and cells. IFSP1 and pcDNA3.1-ACSL4 plasmid were used to knock down Ferroptosis suppressor protein1 (FSP1) and promote the expression of acyl-CoA synthetase long-chain family member 4 (ACSL4) in HepG2 cells. DG improved lipid metabolism disorders and liver damage induced by a high-fat diet in rats with NAFLD. Furthermore, the administration of DG notably decreased oxidative stress levels and liver Fe²⁺ concentrations in rats. Additionally, in vitro experiments demonstrated that DG treatment markedly attenuated ferroptosis and ROS accumulation in HepG2 cells induced by FFAs. Moreover, overexpression of hepatic ACSL4 expression by pcDNA3.1-ACSL4 plasmid promoted the regulatory effects of DG on LPCAT3 and ALOX15. Our research shows that DG can alleviate NAFLD by regulating the FSP1/COQ10 pathway of the ferroptosis defense system and the ACSL4/LPCAT3/ALOX15 pathway of the ferroptosis execution system. Therefore, DG may serve as a novel inhibitor of ferroptosis for the treatment of NAFLD.

100 Deals associated with Diosgenin

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	-	Université de Limoges	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Diosgenin

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation